Key Insights

Highlights

Success Rate

63% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

11.1%

3 terminated out of 27 trials

Success Rate

62.5%

-24.0% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed with results

Key Signals

4 with results63% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (8)
Early P 1 (2)
P 1 (1)
P 2 (11)
P 3 (2)

Trial Status

Active Not Recruiting10
Completed5
Recruiting5
Terminated3
Withdrawn2
Suspended1

Trial Success Rate

62.5%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT03899987Phase 2Active Not Recruiting

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

NCT04215029Not ApplicableActive Not Recruiting

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans

NCT04985565Not ApplicableActive Not Recruiting

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

NCT04037254Phase 1Completed

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NCT07025369Phase 2Recruiting

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

NCT04624256Not ApplicableActive Not Recruiting

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

NCT06330805Phase 2Recruiting

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

NCT03575832Not ApplicableActive Not Recruiting

Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners

NCT04947254Phase 2Recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

NCT05320406Phase 2Active Not Recruiting

RElugolix VErsus LeUprolide Cardiac Trial

NCT06205316Phase 3Recruiting

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

NCT04981834Not ApplicableSuspended

Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer

NCT04189770Active Not Recruiting

Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners

NCT04777071Phase 2Active Not Recruiting

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

NCT04501913Completed

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

NCT04519879Phase 2Active Not Recruiting

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

NCT04253483Phase 2Active Not Recruiting

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

NCT04945642Not ApplicableRecruiting

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

NCT04318028Not ApplicableCompleted

An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer

NCT04927559Terminated

Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy

Scroll to load more

Research Network

Activity Timeline